NasdaqGS:VTRSPharmaceuticals
Mixed Phase 3 Trial Results Might Change The Case For Investing In Viatris (VTRS)
In July 2025, Viatris announced mixed results in late-stage clinical trials, with its pimecrolimus 0.3% ophthalmic ointment for blepharitis failing to meet its primary endpoint, while two other key candidates, MR-142 and MR-141, delivered positive Phase 3 outcomes in keratorefractive conditions and presbyopia.
This combination of disappointing and encouraging trial developments provides a nuanced view of Viatris' research pipeline and its ongoing efforts to address unmet needs in eye care...